Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HK1 | P19367 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | GALK1 | P51570 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | PDE7B | Q9NP56 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4847795 | 0.81 | MAPT (0.40) | MAPTNPC1PDE7APDE7B | |
| SCHEMBL4186361 | 0.66 | MAPT (0.43) | MAPTKDM4ENPC1PDE7APDE7B | |
| SCHEMBL7269283 | 0.65 | HTR3B (0.39) | — | |
| SCHEMBL11250932 | 0.64 | MAPT (0.34) | MAPTPDE7APDE7B | |
| SCHEMBL5753754 | 0.64 | CYP2A6 (0.41) | — | |
| SCHEMBL4501455 | 0.64 | OPRL1 (0.35) | — | |
| SCHEMBL5527062 | 0.64 | MAPT (0.33) | MAPTIDO1 | |
| SCHEMBL829452 | 0.63 | TSHR (0.43) | — | |
| SCHEMBL11251668 | 0.62 | MAPT (0.33) | MAPTPDE7APDE7B | |
| SCHEMBL11251690 | 0.62 | HTR5A (0.44) | PDE7APDE7B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435733-B2 | Mineralocorticoid receptor modulator compounds and methods, and pharmaceutical compositions containing these compounds | LIGAND PHARMACEUTICALS, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20070185102-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | LIGAND PHARMACEUTICALS, INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185102-A1 | MINERALOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | NR3C2, MC2R, NR3C1 | MAPT 2468/4885KDM4E 3549/4885MEN1 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.